Global (AMER, APAC, BRICS and EMEA) Infantile Spasms Therapeutics Market Size, Status and Forecast 2019-2025 (Includes Business Impact of COVID-19)

                                          
Abstract, Snapshot, Market Analysis & Market Definition: Infantile Spasms Therapeutics Market

 

An infantile spasm (IS), also known as West Syndrome, is a specific type of seizure seen in an epilepsy syndrome of infancy and childhood. West Syndrome is characterized by infantile spasms, developmental regression, and a specific pattern on electroencephalography (EEG) testing called hypsarrhythmia (chaotic brain waves). The onset of infantile spasms is usually in the first year of life, typically between 4-8 months. The seizures primarily consist of a sudden bending forward of the body with stiffening of the arms and legs; some children arch their backs as they extend their arms and legs. The condition is usually observed in 2% of childhood epilepsies and 25% of epilepsies that start in the first year of life. The global infantile spasms therapeutics market is growing at a slow pace. This is due to the increased availability of generic drugs and less approved therapies in the market and the less awareness of the disease and the available treatment options, especially in the low- and middle-income countries. The classification of Infantile Spasms Therapeutics includes Oral, Injection. The proportion of Injection in 2016 is about 45%, and the proportion of Oral in 2016 is about 55%. Based on application, the nitinol medical devices market is segmented into Hospital, Clinic and others. Clinic segment accounted for larger market share in terms of sales in 2016, Clinic segmented accounted for more than 45% of the market share in 2016. United States is the largest consumption place, with a consumption market share nearly 83% in 2016. Following United States, Europe is the second largest consumption place with the consumption market share of 12.6% in 2016. The US market is dominated by two approved products H. P. Acthar Gel (adrenocorticotropin hormone) and Sabril (vigabatrin). Sabril was the first drug to be approved by the Food and Drug Administration (FDA) in 2009 and H. P. Acthar Gel (adrenocorticotropin hormone) was approved for infantile spasms in 2010. Both have Orphan Drug Exclusivity (ODE) in the US. In the future, the Infantile Spasms Therapeutics will have a good future; the price fluctuation has relationship with the raw material. The technology will more mature and the industry is more dispersion. In 2018, the global Infantile Spasms Therapeutics market size was 133.6 million US$ and it is expected to reach 170.5 million US$ by the end of 2025, with a CAGR of 3.6% during 2019-2025. This report focuses on the global Infantile Spasms Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Infantile Spasms Therapeutics development in United States, Europe and China. 

Market Segmentation, Outlook & Regional Insights: Infantile Spasms Therapeutics Market

Segmentation by Product Type: Breakdown of data from year 2014 to 2019 and forecast until 2025:

Oral
Injection

Segmentation by Application: Breakdown of data from year 2014 to 2019 and forecast until 2025:


Hospital
Clinic
Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

Key Players, Recent Developments & Sector Viewpoints: Infantile Spasms Therapeutics Market

Mallinckrodt
H. Lundbeck
Insys Therapeutics
Orphelia Pharma
Valerion Therapeutics
Catalyst Pharmaceuticals
Anavex Life Sciences
Retrophin
GW Pharmaceuticals

Key Insights Covered: Exhaustive Infantile Spasms Therapeutics Market
1.  Market size (sales, revenue and growth rate) of Infantile Spasms Therapeutics industry.
2. Global major manufacturers' operating situation (sales, revenue, growth rate and gross margin) of Infantile Spasms Therapeutics industry.
3. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Infantile Spasms Therapeutics industry.
4. Market size (sales, revenue) forecast by regions and countries from 2019 to 2025 of Infantile Spasms Therapeutics industry.

Research Methodology: Infantile Spasms Therapeutics Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please Request a Sample Report.
Demand Side Primary Contributors: OEMs, Industrial Professionals, Researches, Suppliers and Distributors, Group Purchasing Organizations, Associations, Insurers, Universities, Technological Writers, Scientists, Promoters, Investors among others.
Supply Side Primary Contributors: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, Regulatory Affairs Managers among others.